BACKGROUND: We hypothesized that, for methicillin-resistant Staphylococcus aureus (MRSA), in vitro daptomycin susceptibility could be influenced by exposures to endogenous host defense peptides (HDPs) prior to clinical exposure to daptomycin. METHODS: Two endovascular HDPs were used: thrombin-induced platelet microbicidal protein (tPMP) and human neutrophil defensin-1 (hNP-1) from neutrophils. Forty-seven unique MRSA isolates obtained from bacteremic patients in multicenter prospective clinical trials were studied. Clinical characteristics, microbiologic parameters, prior vancomycin therapy, and susceptibilities to tPMP, hNP-1, and daptomycin were compared using univariate and multivariate analyses. RESULTS: All strains were daptomycin susceptible. Daptomycin minimum inhibitory concentrations (MICs) were inversely related to in vitro tPMP (but not hNP-1) killing. Strains with a daptomycin MIC of 1 mg/L exhibited significantly less killing by tPMP, compared with strains with an MIC of ≤ 0.5 mg/L. Prior vancomycin therapy did not influence this relationship. Regression tree modeling confirmed that reduced tPMP-induced killing in vitro was the strongest predictor of higher daptomycin MICs within the daptomycin-susceptible range. CONCLUSIONS: Among daptomycin-susceptible MRSA isolates from patients who had never received daptomycin, higher daptomycin MICs tracked with increased resistance to killing by platelet-derived but not neutrophil-derived HDPs. These findings support the notion that endogenous exposure of MRSA to specific HDPs may play a role in selecting strains with an intrinsically higher daptomycin MIC phenotype.
BACKGROUND: We hypothesized that, for methicillin-resistant Staphylococcus aureus (MRSA), in vitro daptomycin susceptibility could be influenced by exposures to endogenous host defense peptides (HDPs) prior to clinical exposure to daptomycin. METHODS: Two endovascular HDPs were used: thrombin-induced platelet microbicidal protein (tPMP) and humanneutrophil defensin-1 (hNP-1) from neutrophils. Forty-seven unique MRSA isolates obtained from bacteremic patients in multicenter prospective clinical trials were studied. Clinical characteristics, microbiologic parameters, prior vancomycin therapy, and susceptibilities to tPMP, hNP-1, and daptomycin were compared using univariate and multivariate analyses. RESULTS: All strains were daptomycin susceptible. Daptomycin minimum inhibitory concentrations (MICs) were inversely related to in vitro tPMP (but not hNP-1) killing. Strains with a daptomycin MIC of 1 mg/L exhibited significantly less killing by tPMP, compared with strains with an MIC of ≤ 0.5 mg/L. Prior vancomycin therapy did not influence this relationship. Regression tree modeling confirmed that reduced tPMP-induced killing in vitro was the strongest predictor of higher daptomycin MICs within the daptomycin-susceptible range. CONCLUSIONS: Among daptomycin-susceptible MRSA isolates from patients who had never received daptomycin, higher daptomycin MICs tracked with increased resistance to killing by platelet-derived but not neutrophil-derived HDPs. These findings support the notion that endogenous exposure of MRSA to specific HDPs may play a role in selecting strains with an intrinsically higher daptomycin MIC phenotype.
Authors: Kati Seidl; Arnold S Bayer; Vance G Fowler; James A McKinnell; Wessam Abdel Hady; George Sakoulas; Michael R Yeaman; Yan Q Xiong Journal: Antimicrob Agents Chemother Date: 2010-11-22 Impact factor: 5.191
Authors: Carlo McCalla; Davida S Smyth; D Ashley Robinson; Judith Steenbergen; Steven A Luperchio; Pamela A Moise; Vance G Fowler; George Sakoulas Journal: Antimicrob Agents Chemother Date: 2008-07-07 Impact factor: 5.191
Authors: Natasha E Holmes; John D Turnidge; Wendy J Munckhof; James O Robinson; Tony M Korman; Matthew V N O'Sullivan; Tara L Anderson; Sally A Roberts; Wei Gao; Keryn J Christiansen; Geoffrey W Coombs; Paul D R Johnson; Benjamin P Howden Journal: J Infect Dis Date: 2011-08-01 Impact factor: 5.226
Authors: Marin L Schweizer; Jon P Furuno; George Sakoulas; J Kristie Johnson; Anthony D Harris; Michelle D Shardell; Jessina C McGregor; Kerri A Thom; Eli N Perencevich Journal: Antimicrob Agents Chemother Date: 2010-12-20 Impact factor: 5.191
Authors: Pamela A Moise; Alan Forrest; Arnold S Bayer; Yan Q Xiong; Michael R Yeaman; George Sakoulas Journal: J Infect Dis Date: 2010-01-15 Impact factor: 5.226
Authors: Soo-Jin Yang; Barry N Kreiswirth; George Sakoulas; Michael R Yeaman; Yan Q Xiong; Ayumi Sawa; Arnold S Bayer Journal: J Infect Dis Date: 2009-12-15 Impact factor: 5.226
Authors: Pamela A Moise; Davida S Smyth; D Ashley Robinson; Nadia El-Fawal; Carlo McCalla; George Sakoulas Journal: J Antimicrob Chemother Date: 2009-03-03 Impact factor: 5.790
Authors: Rachel E Jenson; Sarah L Baines; Benjamin P Howden; Nagendra N Mishra; Sabrina Farah; Cassandra Lew; Andrew D Berti; Sanjay K Shukla; Arnold S Bayer; Warren E Rose Journal: Antimicrob Agents Chemother Date: 2020-08-20 Impact factor: 5.191
Authors: Wei Gao; David R Cameron; John K Davies; Xenia Kostoulias; Justin Stepnell; Kellie L Tuck; Michael R Yeaman; Anton Y Peleg; Timothy P Stinear; Benjamin P Howden Journal: J Infect Dis Date: 2012-12-18 Impact factor: 5.226
Authors: Lorena Diaz; Truc T Tran; Jose M Munita; William R Miller; Sandra Rincon; Lina P Carvajal; Aye Wollam; Jinnethe Reyes; Diana Panesso; Natalia L Rojas; Yousif Shamoo; Barbara E Murray; George M Weinstock; Cesar A Arias Journal: Antimicrob Agents Chemother Date: 2014-05-27 Impact factor: 5.191
Authors: George Sakoulas; Cheryl Y Okumura; Wdee Thienphrapa; Joshua Olson; Poochit Nonejuie; Quang Dam; Abhay Dhand; Joseph Pogliano; Michael R Yeaman; Mary E Hensler; Arnold S Bayer; Victor Nizet Journal: J Mol Med (Berl) Date: 2013-12-03 Impact factor: 4.599
Authors: Arnold S Bayer; Nagendra N Mishra; Liang Chen; Barry N Kreiswirth; Aileen Rubio; Soo-Jin Yang Journal: Antimicrob Agents Chemother Date: 2015-06-08 Impact factor: 5.191